BR112022007099A2 - Conjugados de fármaco de ligante de peptídeo bicíclico - Google Patents

Conjugados de fármaco de ligante de peptídeo bicíclico

Info

Publication number
BR112022007099A2
BR112022007099A2 BR112022007099A BR112022007099A BR112022007099A2 BR 112022007099 A2 BR112022007099 A2 BR 112022007099A2 BR 112022007099 A BR112022007099 A BR 112022007099A BR 112022007099 A BR112022007099 A BR 112022007099A BR 112022007099 A2 BR112022007099 A2 BR 112022007099A2
Authority
BR
Brazil
Prior art keywords
drug conjugates
peptide binding
bicyclic peptide
binding drug
relates
Prior art date
Application number
BR112022007099A
Other languages
English (en)
Inventor
Beswick Paul
Mudd Gemma
Rigby Michael
Original Assignee
Bicycletx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bicycletx Ltd filed Critical Bicycletx Ltd
Publication of BR112022007099A2 publication Critical patent/BR112022007099A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

CONJUGADOS DE FÁRMACO DE LIGANTE DE PEPTÍDEO BICÍCLICO. A presente invenção refere-se aos conjugados de fármaco compreendendo pelo menos dois polipeptídeos que estão cada ligado covalentemente às estruturas moleculares não aromáticas, de modo que duas ou mais alças peptídicas sejam subtendidas entre os pontos de ligação à estrutura. A invenção também se refere a composições farmacêuticas compreendendo os referidos conjugados de fármaco e ao uso dos referidos conjugados de fármaco na prevenção, supressão ou tratamento de doenças, tais como, aquelas que podem ser aliviadas por morte celular, em particular, doenças caracterizadas por tipos celulares defeituosos, distúrbios proliferativos, tal como, câncer e distúrbios autoimunes, tal como, artrite reumatoide.
BR112022007099A 2019-10-15 2020-10-15 Conjugados de fármaco de ligante de peptídeo bicíclico BR112022007099A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201914872A GB201914872D0 (en) 2019-10-15 2019-10-15 Bicyclic peptide ligand drug conjugates
PCT/GB2020/052590 WO2021074622A1 (en) 2019-10-15 2020-10-15 Bicyclic peptide ligand drug conjugates

Publications (1)

Publication Number Publication Date
BR112022007099A2 true BR112022007099A2 (pt) 2022-07-05

Family

ID=68619460

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022007099A BR112022007099A2 (pt) 2019-10-15 2020-10-15 Conjugados de fármaco de ligante de peptídeo bicíclico

Country Status (12)

Country Link
US (1) US20240173422A1 (pt)
EP (1) EP4045089A1 (pt)
JP (1) JP2022552839A (pt)
KR (1) KR20220088416A (pt)
CN (1) CN114901317A (pt)
AU (1) AU2020367325A1 (pt)
BR (1) BR112022007099A2 (pt)
CA (1) CA3154672A1 (pt)
GB (1) GB201914872D0 (pt)
IL (1) IL292113A (pt)
MX (1) MX2022004572A (pt)
WO (1) WO2021074622A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB202016331D0 (en) * 2020-10-15 2020-12-02 Bicyclerd Ltd Bicyclic peptide ligand drug conjugates
WO2022253051A1 (zh) * 2021-06-01 2022-12-08 南京明德新药研发有限公司 多肽偶联药物及其应用
GB202114279D0 (en) * 2021-10-06 2021-11-17 Bicycletx Ltd Bicyclic peptide ligand drug conjugates
WO2023066314A1 (zh) * 2021-10-19 2023-04-27 海思科医药集团股份有限公司 Nectin-4的双环肽配体及其用途
CN116768978A (zh) * 2022-03-11 2023-09-19 上海智肽生物科技有限公司 Nectin-4靶向肽化合物及其药物偶联物
CN117003830A (zh) * 2023-08-04 2023-11-07 湖南中晟全肽生化有限公司 靶向Nectin-4的多肽及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
PT1844337E (pt) 2005-01-24 2014-04-03 Pepscan Systems Bv Compostos ligantes, compostos imunogénicos e peptidomiméticos
EP2653543A1 (en) 2008-02-05 2013-10-23 Bicycle Therapeutics Limited Methods and Compositions
PT3215518T (pt) 2014-10-29 2021-05-25 Bicyclerd Ltd Ligantes de péptido bicíclicos específicos para mt1-mmp
BR112020014576A2 (pt) * 2018-02-23 2020-12-08 Bicycletx Limited Ligantes peptídicos bicíclicos multiméricos
CA3095582A1 (en) * 2018-04-04 2019-10-10 Bicycletx Limited Heterotandem bicyclic peptide complexes
US11180531B2 (en) * 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4

Also Published As

Publication number Publication date
KR20220088416A (ko) 2022-06-27
EP4045089A1 (en) 2022-08-24
MX2022004572A (es) 2022-05-06
GB201914872D0 (en) 2019-11-27
IL292113A (en) 2022-06-01
CN114901317A (zh) 2022-08-12
JP2022552839A (ja) 2022-12-20
AU2020367325A1 (en) 2022-05-26
CA3154672A1 (en) 2021-04-22
US20240173422A1 (en) 2024-05-30
WO2021074622A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
BR112022007099A2 (pt) Conjugados de fármaco de ligante de peptídeo bicíclico
BR112018000366A2 (pt) polipeptídeo de fusão, muteína de lipocalina, molécula de ácido nucleico, célula hospedeira, métodos de produção de um polipeptídeo de fusão, para inibir simultaneamente os pontos de controle imunes, para aumentar a atividade celular de linfócitos antitumorais e para interferir com a ligação do lag-3 humano e uso do polipeptídeo de fusão
SA520412268B1 (ar) EphA2 مركبات ترابطية من ببتيدات ثنائية الحلقة خاصة بـ
CL2019001324A1 (es) Anticuerpos anti-met, moleculas de unión a antígeno bispecificas que se unen a met y métodos de uso de los mismos.
CO2017009954A2 (es) Dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúmina
BR112018011781A2 (pt) molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica
CL2021003196A1 (es) Terapias combinadas dirigidas a pd-1, tim-3, y lag-3 (divisional de solicitud n° 201902850)
SG11201807936VA (en) Cell injury inducing therapeutic drug for use in cancer therapy
PH12020552179A1 (en) Bicyclic peptide ligands specific for nectin-4
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
BR112019007714A2 (pt) anticorpos de 4-1bb anti-humanos e usos dos mesmos
BR112018008011A2 (pt) proteínas de ligação triespecíficas e/ou trivalentes para prevenção ou tratamento de infecção por hiv
BR112018012794A2 (pt) receptor de célula t, tcr que se liga a um complexo hla-a*02 sllmwitqc, fusão anti-cd3 de tcr, ácido nucléico, vetor de expressão, célula que ocorre e/ou purificada e/ou concebida de maneira não natural, célula, composição farmacêutica, método de tratamento de um indivíduo humano, formulação injetável para administração a um indivíduo humano, e método de produção de uma tcr
BR112019004764A2 (pt) inibidores bicíclicos fundidos da interação menina-mll
BR112021022315A2 (pt) Ligantes de peptídeo bicíclicos específicos para ox40
BR112018073676A2 (pt) lipossomas peguilados e métodos de uso
MX2019013690A (es) Conjugados de farmaco-proteina con ciclodextrina.
AR102595A1 (es) Anticuerpos anti-ang2 y métodos de utilización
EA201792487A1 (ru) Композиции гидроксипропил-бета-циклодекстринов и способы
BR112019008349A2 (pt) composição de peptídeos, e, utilização de uma composição.
BR112018077139A2 (pt) anticorpos anti-met e seus usos
BR112016025764A2 (pt) vacina de peptídeo compreendendo peptídeo ras mutante e agente quimioterapêutico
EA202191244A1 (ru) Новые цитостатические конъюгаты с лигандами интегрина
BR112015025025A2 (pt) composições terapêuticas e usos das mesmas
BR112017011552A2 (pt) derivados de fgf21 e seu uso

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]